nach oben

Pediatric Surgery International

Erschienen in:

15.09.2022 | Original Article

Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms’ tumor

verfasst von: Dinesh Kumar Sahu, Neetu Singh, Mumani Das, Jiledar Rawat, Devendra Kumar Gupta

Erschienen in: Pediatric Surgery International | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Wilms’ tumor is the most-frequent malignant-kidney tumor in children under 3–4 years of age and is caused by genetic alterations of oncogenes (OG) and tumor-suppressor genes (TG). Wilms’ tumor has been linked to many OG-&-TG. However, only WT1 has a proven role in the development of this embryonic-tumor.

Methods

The study investigates the level of mRNA expression of 16 OGs and 20 TGs involved in key-signaling pathways, including chromatin modification; RAS; APC; Cell Cycle/Apoptosis; Transcriptional Regulation; PI3K; NOTCH-&-HH; PI3K & RAS of 24-fresh Wilms’-tumor cases by capture-and-reporter probe Code-Sets chemistry, as CNVs in these pathway genes have been reported.

Results

Upon extensively investigating, MEN1, MLL2, MLL3, PBRM1, PRDM1, SMARCB1, SETD2, WT1, PTPN11, KRAS, HRAS, NF1, APC, RB1, FUBP1, BCOR, U2AF1, PIK3CA, PTEN, EBXW7, SMO, ALK, CBL, EP300-and-GATA1 were found to be significantly up-regulated in 58.34, 62.5, 79.17, 91.67, 58, 66.66,54, 58.34, 66.67, 75, 62.5, 62.5, 58, 79.17, 79.17, 75, 70.84, 50, 50, 75, 66.66, 62.50, 61.66, 58.34-and-62.50% of cases respectively, whereas BRAF, NF2, CDH1, BCL2, FGFR3, ERBB2, MET, RET, EGFR-and-GATA2 were significantly down regulated in 58, 87.50, 79.16, 54.16, 79.17, 91.66, 66.66, 58.33, 91.66-and-62.50% of cases, respectively. Interestingly, the WT1 gene was five-fold down regulated in 41.66% of cases only.

Conclusion

Hence, extensive profiling of OGs and TGs association of major-signaling pathways in Wilms’ tumor cases may aid in disease diagnosis. PBRM1 (up-regulated in 91.67% of cases), ERBB2 and EGFR (down-regulated in 91.66 and 91.66% of cases, respectively) could be marker genes. However, validation of all relevant results in a larger number of samples is required.

Nur mit Berechtigung zugänglich

(2002) Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries, Bethesda (MD)

Breslow NE, Olson J, Moksness J, Beckwith JB, Grundy P (1996) Familial Wilms’ tumor: a descriptive study. Med Pediatr Oncol 27:398–403. https://doi.org/10.1002/(SICI)1096-911X(199611)27:5%3c398::AID-MPO2%3e3.0.CO;2-HCrossRefPubMed

McDonald JM, Douglass EC, Fisher R, Geiser CF, Krill CE, Strong LC, Virshup D, Huff V (1998) Linkage of familial Wilms’ tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 58:1387–1390PubMed

Rahman N, Arbour L, Tonin P, Renshaw J, Pelletier J, Baruchel S, Pritchard-Jones K, Stratton MR, Narod SA (1996) Evidence for a familial Wilms’ tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet 13:461–463. https://doi.org/10.1038/ng0896-461CrossRefPubMed

Popov SD, Sebire NJ, Vujanic GM. (2016) Wilms’ tumour—histology and differential diagnosis. In: van den Heuvel-Eibrink MM. (ed). Wilms Tumor, Brisbane (AU)

Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, Pritchard-Jones K (2013) Is Wilms tumor a candidate neoplasia for treatment with WNT/beta-catenin pathway modulators?–A report from the renal tumors biology-driven drug development workshop. Mol Cancer Ther 12:2619–2627. https://doi.org/10.1158/1535-7163.MCT-13-0335CrossRefPubMed

Coppes MJ, de Kraker J, van Dijken PJ, Perry HJ, Delemarre JF, Tournade MF, Lemerle J, Voute PA (1989) Bilateral Wilms’ tumor: long-term survival and some epidemiological features. J Clin Oncol 7:310–315. https://doi.org/10.1200/JCO.1989.7.3.310CrossRefPubMed

Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823. https://doi.org/10.1073/pnas.68.4.820CrossRefPubMedPubMedCentral

Knudson AG Jr, Strong LC (1972) Mutation and cancer: a model for Wilms’ tumor of the kidney. J Natl Cancer Inst 48:313–324PubMed

10.

Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE (1991) WT1 mutations contribute to abnormal genital system development and hereditary Wilms’ tumour. Nature 353:431–434. https://doi.org/10.1038/353431a0CrossRefPubMed

11.

Segers H, Kersseboom R, Alders M, Pieters R, Wagner A, van den Heuvel-Eibrink MM (2012) Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. Eur J Cancer 48:3249–3256. https://doi.org/10.1016/j.ejca.2012.06.008CrossRefPubMed

12.

Berger AH, Knudson AG, Pandolfi PP (2011) A continuum model for tumour suppression. Nature 476:163–169. https://doi.org/10.1038/nature10275CrossRefPubMedPubMedCentral

13.

Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799. https://doi.org/10.1038/nm1087CrossRefPubMed

14.

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495–501. https://doi.org/10.1038/nature12912CrossRefPubMedPubMedCentral

15.

Gao J, Ciriello G, Sander C, Schultz N (2014) Collection, integration and analysis of cancer genomic profiles: from data to insight. Curr Opin Genet Dev 24:92–98. https://doi.org/10.1016/j.gde.2013.12.003CrossRefPubMedPubMedCentral

16.

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218. https://doi.org/10.1038/nature12213CrossRefPubMedPubMedCentral

17.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, PedBrain I, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR, Australian Pancreatic Cancer Genome I, Consortium IBC, Consortium IM-S (2013) Signatures of mutational processes in human cancer. Nature 500:415–421. https://doi.org/10.1038/nature12477CrossRefPubMedPubMedCentral

18.

Gadd S, Huff V, Walz AL, Ooms A, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ (2017) A children’s oncology group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet 49:1487–1494. https://doi.org/10.1038/ng.3940CrossRefPubMedPubMedCentral

19.

Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M (2009) WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 48:1102–1111. https://doi.org/10.1002/gcc.20712CrossRefPubMed

20.

Ruteshouser EC, Robinson SM, Huff V (2008) Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47:461–470. https://doi.org/10.1002/gcc.20553CrossRefPubMedPubMedCentral

21.

Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Bowlby R, Brooks D, Ma Y, Mungall AJ, Moore RA, Schein J, Marra MA, Huff V, Dome JS, Chi YY, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Jafari N, Ross N, Gastier-Foster JM, Perlman EJ (2015) Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286–297. https://doi.org/10.1016/j.ccell.2015.01.003CrossRefPubMedPubMedCentral

22.

Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O’Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M (2015) Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27:298–311. https://doi.org/10.1016/j.ccell.2015.01.002CrossRefPubMed

23.

Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, Mendell JT, Amatruda JF (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802. https://doi.org/10.1038/ncomms5802CrossRefPubMed

24.

Torrezan GT, Ferreira EN, Nakahata AM, Barros BD, Castro MT, Correa BR, Krepischi AC, Olivieri EH, Cunha IW, Tabori U, Grundy PE, Costa CM, de Camargo B, Galante PA, Carraro DM (2014) Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun 5:4039. https://doi.org/10.1038/ncomms5039CrossRefPubMed

25.

Hanks S, Perdeaux ER, Seal S, Ruark E, Mahamdallie SS, Murray A, Ramsay E, Del Vecchio DS, Zachariou A, de Souza B, Warren-Perry M, Elliott A, Davidson A, Price H, Stiller C, Pritchard-Jones K, Rahman N (2014) Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. Nat Commun 5:4398. https://doi.org/10.1038/ncomms5398CrossRefPubMed

26.

Mahamdallie SS, Hanks S, Karlin KL, Zachariou A, Perdeaux ER, Ruark E, Shaw CA, Renwick A, Ramsay E, Yost S, Elliott A, Birch J, Capra M, Gray J, Hale J, Kingston J, Levitt G, McLean T, Sheridan E, Renwick A, Seal S, Stiller C, Sebire N, Westbrook TF, Rahman N (2015) Mutations in the transcriptional repressor REST predispose to Wilms tumor. Nat Genet 47:1471–1474. https://doi.org/10.1038/ng.3440CrossRefPubMed

27.

Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J (1994) Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91–97. https://doi.org/10.1038/ng0594-91CrossRefPubMed

28.

el Bahtimi R, Hazen-Martin DJ, Re GG, Willingham MC, Garvin AJ (1996) Immunophenotype, mRNA expression, and gene structure of p53 in Wilms’ tumors. Mod Pathol 9:238–244PubMed

29.

Wallkamm V, Dorlich R, Rahm K, Klessing T, Nienhaus GU, Wedlich D, Gradl D (2014) Live imaging of Xwnt5A-ROR2 complexes. PLoS ONE 9:e109428. https://doi.org/10.1371/journal.pone.0109428CrossRefPubMedPubMedCentral

30.

Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K, Children’s C, Leukaemia G and Group SWTB (2010) Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor. Clin Cancer Res 16:2036–2045. https://doi.org/10.1158/1078-0432.CCR-09-2890CrossRefPubMedPubMedCentral

31.

Mahamdallie S, Yost S, Poyastro-Pearson E, Holt E, Zachariou A, Seal S, Elliott A, Clarke M, Warren-Perry M, Hanks S, Anderson J, Bomken S, Cole T, Farah R, Furtwaengler R, Glaser A, Grundy R, Hayden J, Lowis S, Millot F, Nicholson J, Ronghe M, Skeen J, Williams D, Yeomanson D, Ruark E, Rahman N (2019) Identification of new Wilms tumour predisposition genes: an exome sequencing study. Lancet Child Adolesc Health 3:322–331. https://doi.org/10.1016/S2352-4642(19)30018-5CrossRefPubMedPubMedCentral

32.

Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ (2016) Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the children’s oncology group. J Clin Oncol 34:3189–3194. https://doi.org/10.1200/JCO.2015.66.1140CrossRefPubMedPubMedCentral

33.

Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanic G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O’Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K (2016) Gain of 1q as a prognostic biomarker in wilms tumors (WTs) treated with preoperative chemotherapy in the international society of paediatric oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study. J Clin Oncol 34:3195–3203. https://doi.org/10.1200/JCO.2015.66.0001CrossRefPubMedPubMedCentral

34.

Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D’Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM, National Wilms Tumor Study G (2005) Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312–7321. https://doi.org/10.1200/JCO.2005.01.2799CrossRefPubMed

35.

Muller EA, Aradhya S, Atkin JF, Carmany EP, Elliott AM, Chudley AE, Clark RD, Everman DB, Garner S, Hall BD, Herman GE, Kivuva E, Ramanathan S, Stevenson DA, Stockton DW, Hudgins L (2012) Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia, and developmental delay. Am J Med Genet A 158A:391–399. https://doi.org/10.1002/ajmg.a.34216CrossRefPubMed

36.

Isidor B, Bourdeaut F, Lafon D, Plessis G, Lacaze E, Kannengiesser C, Rossignol S, Pichon O, Briand A, Martin-Coignard D, Piccione M, David A, Delattre O, Jeanpierre C, Sevenet N, Le Caignec C (2013) Wilms’ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. Eur J Hum Genet 21:784–787. https://doi.org/10.1038/ejhg.2012.252CrossRefPubMed

37.

Martins AG, Pinto AT, Domingues R, Cavaco BM (2018) Identification of a novel CTR9 germline mutation in a family with Wilms tumor. Eur J Med Genet 61:294–299. https://doi.org/10.1016/j.ejmg.2017.12.010CrossRefPubMed

38.

Singh N, Sahu DK, Goel M, Kant R, Gupta DK (2015) Retrospective analysis of FFPE based Wilms’ tumor samples through copy number and somatic mutation related molecular inversion probe based array. Gene 565:295–308. https://doi.org/10.1016/j.gene.2015.04.051CrossRefPubMed

39.

Naing L, Winn T, Rusli BN (2006) Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 1:9–14

40.

Kumar NA, Bezawada S, Chaitanya SV, Gouri SRS, Pulla P (2016) A retrospective study of Wilms tumour in our institute. Int J Contemp Med Res 3(8):2223–2225

41.

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159. https://doi.org/10.1006/abio.1987.9999CrossRefPubMed

42.

Malkov VA, Serikawa KA, Balantac N, Watters J, Geiss G, Mashadi-Hossein A, Fare T (2009) Multiplexed measurements of gene signatures in different analytes using the nanostring nCounter assay system. BMC Res Notes 2:80. https://doi.org/10.1186/1756-0500-2-80CrossRefPubMedPubMedCentral

43.

Bentley-Hewitt KL, Hedderley DI, Monro J, Martell S, Smith H, Mishra S (2016) Comparison of quantitative real-time polymerase chain reaction with NanoString(R) methodology using adipose and liver tissues from rats fed seaweed. N Biotechnol 33:380–386. https://doi.org/10.1016/j.nbt.2016.01.002CrossRefPubMed

44.

Carraro DM, Ramalho RF, Maschietto M. (2016) Gene Expression in Wilms tumor: disturbance of the Wnt signaling pathway and MicroRNA biogenesis. In: van den Heuvel-Eibrink MM (ed). Wilms Tumor, Brisbane (AU)

45.

Xu B, Zeng DQ, Wu Y, Zheng R, Gu L, Lin X, Hua X, Jin GH (2011) Tumor suppressor menin represses paired box gene 2 expression via Wilms tumor suppressor protein-polycomb group complex. J Biol Chem 286:13937–13944. https://doi.org/10.1074/jbc.M110.197830CrossRefPubMedPubMedCentral

46.

Wagner KD, Wagner N, Schedl A (2003) The complex life of WT1. J Cell Sci 116:1653–1658. https://doi.org/10.1242/jcs.00405CrossRefPubMed

47.

Sigauke E, Rakheja D, Maddox DL, Hladik CL, White CL, Timmons CF, Raisanen J (2006) Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol 19:717–725. https://doi.org/10.1038/modpathol.3800581CrossRefPubMed

48.

Zlobin A, Wyatt D, Varsanik M, Dingwall A, Osipo C (2018) Roles for MLL2/KMT2D or MLL3/KMT2C in HER+ breast cancer stem cells. Cancer Res 78(13_Supplement):5845. https://doi.org/10.1158/1538-7445.AM2018-5845CrossRef

49.

Khailany RA, Igci M, Bayraktar E, Erturhan S, Karakok M, Arslan A (2015) VHL, PBRM1 and SETD2 genes in kidney cancer: a molecular investigation. Int J Med Health Sci. https://doi.org/10.5281/zenodo.1106329CrossRef

50.

Dalpa E, Gourvas V, Soulitzis N, Spandidos DA (2017) K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth. Med Oncol 34:6. https://doi.org/10.1007/s12032-016-0862-5CrossRefPubMed

51.

Stay EJ, Vawter G (1977) The relationship between nephroblastoma and neurofibromatosis (Von Recklinghausen’s disease). Cancer 39:2550–2555. https://doi.org/10.1002/1097-0142(197706)39:6%3c2550::aid-cncr2820390636%3e3.0.co;2-yCrossRefPubMed

52.

Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL (2009) Neurofibromatosis type 1 revisited. Pediatrics 123:124–133. https://doi.org/10.1542/peds.2007-3204CrossRefPubMed

53.

Maschietto M, de Camargo B, Brentani H, Grundy P, Sredni ST, Torres C, Mota LD, Cunha IW, Patrao DF, Costa CM, Soares FA, Brentani RR, Carraro DM (2008) Molecular profiling of isolated histological components of wilms tumor implicates a common role for the Wnt signaling pathway in kidney and tumor development. Oncology 75:81–91. https://doi.org/10.1159/000155210CrossRefPubMed

54.

Henderson BR, Fagotto F (2002) The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 3:834–839. https://doi.org/10.1093/embo-reports/kvf181CrossRefPubMedPubMedCentral

55.

Wu C, Zhu W, Qian J, He S, Wu C, Chen Y, Shu Y (2013) WT1 promotes invasion of NSCLC via suppression of CDH1. J Thorac Oncol 8:1163–1169. https://doi.org/10.1097/JTO.0b013e31829f6a5fCrossRefPubMed

56.

Re GG, Hazen-Martin DJ, El Bahtimi R, Brownlee NA, Willingham MC, Garvin AJ (1999) Prognostic significance of Bcl-2 in Wilms’ tumor and oncogenic potential of Bcl-X(L) in rare tumor cases. Int J Cancer 84:192–200. https://doi.org/10.1002/(sici)1097-0215(19990420)84:2%3c192::aid-ijc17%3e3.0.co;2-1CrossRefPubMed

57.

Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S (2019) The genetic changes of Wilms tumour. Nat Rev Nephrol 15:240–251. https://doi.org/10.1038/s41581-019-0112-0CrossRefPubMed

58.

Madsen RR, Vanhaesebroeck B, Semple RK (2018) Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med 24:856–870. https://doi.org/10.1016/j.molmed.2018.08.003CrossRefPubMedPubMedCentral

59.

Griff JR, Duffy KA, Kalish JM (2020) Characterization and childhood tumor risk assessment of genetic and epigenetic syndromes associated with lateralized overgrowth. Front Pediatr 8:613260. https://doi.org/10.3389/fped.2020.613260CrossRefPubMedPubMedCentral

60.

Lu H, Tan Y, Chen L (2019) A clinical study on the expression of PTEN in renal cell carcinoma in children. Oncol Lett 17:69–72. https://doi.org/10.3892/ol.2018.9571CrossRefPubMed

61.

Cui M, Liu W, Zhang L, Guo F, Liu Y, Chen F, Liu T, Ma R, Wu R (2017) Over-EXPRESSION of miR-21 and lower PTEN Levels in Wilms’ tumor with aggressive behavior. Tohoku J Exp Med 242:43–52. https://doi.org/10.1620/tjem.242.43CrossRefPubMed

62.

Hartwig S, Ho J, Pandey P, Macisaac K, Taglienti M, Xiang M, Alterovitz G, Ramoni M, Fraenkel E, Kreidberg JA (2010) Genomic characterization of Wilms’ tumor suppressor 1 targets in nephron progenitor cells during kidney development. Development 137:1189–1203. https://doi.org/10.1242/dev.045732CrossRefPubMedPubMedCentral

63.

Vasei M, Modjtahedi H, Ale-Booyeh O, Mosallaei A, Kajbafzadeh AM, Shahriari M, Ghaderi AA, Soleymanpour H, Kosari F, Moch H, Sauter G (2009) Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet 194:88–95. https://doi.org/10.1016/j.cancergencyto.2009.06.003CrossRefPubMed

64.

Takita J (2017) The role of anaplastic lymphoma kinase in pediatric cancers. Cancer Sci 108:1913–1920. https://doi.org/10.1111/cas.13333CrossRefPubMedPubMedCentral

65.

Cancilla B, Ford-Perriss MD, Bertram JF (1999) Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney. Kidney Int 56:2025–2039. https://doi.org/10.1046/j.1523-1755.1999.00781.xCrossRefPubMed

66.

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK (2000) Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95:992–998CrossRef

67.

Sturla LM, Merrick AE, Burchill SA (2003) FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 89:1276–1284. https://doi.org/10.1038/sj.bjc.6601249CrossRefPubMedPubMedCentral

68.

Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, Kikuchi R, Iwasaki T, Takagi A, Kojima T, Suzuki M, Abe A, Naoe T, Murate T (2009) GATA-1 and GATA-2 binding to 3’ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia 23:1270–1277. https://doi.org/10.1038/leu.2009.13CrossRefPubMed

Titel: Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms’ tumor
verfasst von: Dinesh Kumar Sahu
Neetu Singh
Mumani Das
Jiledar Rawat
Devendra Kumar Gupta
Publikationsdatum: 15.09.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 11/2022
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-022-05202-2

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms’ tumor

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Update Pädiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Serum neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic tool in pediatric acute appendicitis: a prospective validation study

Letter to the Editor in reference to the article entitled ‘Fiberoptic endoscopic evaluation of swallowing (FEES) study: the first report in children to evaluate the oropharyngeal dysphagia after esophageal atresia repair’

Laparoscopic versus open repair of congenital duodenal obstruction: a systematic review and meta-analysis

Intrauterine exposure to oxidative stress induces caspase-1-dependent enteric nerve cell pyroptosis

Laparoscopy ıs a defınıtıve dıagnostıc method for auto-amputated ovary ın ınfants

Endoscopic septum division of tubular esophageal duplication in two children and systematic review

Neu im Fachgebiet Pädiatrie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Update Pädiatrie